



Prior Authorization Criteria

Drug: Breast Cancer Primary Prevention Coverage of Raloxifene and Tamoxifen

P&T Reviewed: 10/14

Description:

ConnectiCare includes the coverage of select medications that are the subject of category A or B recommendations made by the United States Preventive Services Task Force (USPSTF) in accordance with the PPACA mandate. The USPSTF recommendations include statements regarding a broad range of clinical preventive health care services such as screening and counseling. In some select cases the USPSTF recommendation statements provide information to prescribers regarding medication therapy.

In September 2013 the USPSTF updated its recommendation, previously released in 2002, which focused on preventive medications for breast cancer. The revised recommendation statement suggests that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk.

Criteria:

Connecticare will provide coverage of tamoxifen and raloxifene at zero cost share when prescribed for use in primary prevention of invasive breast cancer in women ≥ 35 years of age who meet all of the below criteria:

- Member does not have a prior history of a diagnosis of breast cancer, ductal carcinoma in situ (DCIS), or lobular carcinoma in situ (LCIS)
- Member is being prescribed tamoxifen or raloxifene for the purpose of primary prevention on invasive breast cancer because patient is deemed high risk
- Member is post-menopausal, if prescribed raloxifene

Medications Eligible:

- Generic tamoxifen
- Generic raloxifene
- Soltamox (tamoxifen liquid)- coverage allowed when patient meets all other criteria and cannot swallow or has documented swallowing difficulty.

The above criteria is based on the following reference(s):

1. Requirements under the Affordable Care Act. Department of the Treasury. Internal Revenue Service. 26 C.F.R. 54.9815-2713T(a)(4); Department of Labor, 29 C.F.R. 2590.715-2713(a)(4); and Department of Health and Human Services, 45 C.F.R. 147.130(a)(4).
2. Medications for Risk Reduction of Primary Breast Cancer in Women. United States Preventive Services Task Force. September 2013.
Accessed at: <http://www.uspreventiveservicestaskforce.org/uspstf/uspbrpv.htm>